Antiplatelet treatment

DRUG2 trials

Sponsors

University of Calgary, Hamilton Health Sciences Corporation

Conditions

AspirinPlatelet Dysfunction Due to DrugsStroke, AcuteTicagrelorTransfusion

Phase 3

A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

CompletedNCT02398656

University of CalgaryStroke, Acute

Start: 2015-04-01End: 2024-04-10Updated: 2025-01-31

Unknown Phase

Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets

Hamilton Health Sciences CorporationAspirin, Platelet Dysfunction Due to Drugs, Ticagrelor +1

Start: 2017-01-31End: 2018-01-31Target: 10Updated: 2017-04-06

Related Papers

Association of Successful Recanalization and Functional Outcomes in Minor Ischemic Stroke With Proven Occlusion: A Secondary Analysis of TEMPO-2 Trial

Stroke2026-06-19

Outcomes After Minor Ischemic Stroke in Older Patients Treated With IV Thrombolysis vs Standard of Care in the TEMPO-2 Trial.

2026-04-14

Thrombolysis With Tenecteplase for Minor Disabling Stroke: Secondary Analysis of the TEMPO-2 Randomized Clinical Trial.

2025-12-011 citations

Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial.

2024-12-303 citations

Automatic Matching Algorithms to Identify Eligible Participants for Stroke Trials: A Proof-of-Concept Study

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2024-12-051 citations

Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.

2024-05-1775 citations

Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.

2015-01-0130 citations